Successful pancreaticoduodenectomy for ampullary carcinoma in a patient with diabetes and stable chronic lymphocytic leukemia: a case report emphasizing multidisciplinary optimization Authors: Binazir Khanabadi, Hesameddin Eghlimi, Zeinab Asghari, Tala Tabrizi Published: 2026 ABSTRACT BackgroundPancreaticoduodenectomy (PD) for ampullary carcinoma carries significant risks, and the presence of hematologic comorbidities adds further complexity. While stable Chronic Lymphocytic Leukemia (CLL) is not a contraindication, it complicates perioperative risk stratification and infection control.Case presentationA 66-year-old male with type 2 diabetes mellitus (DM) and stable, untreated Rai Stage I chronic lymphocytic leukemia (CLL) presented with a three-week history of painless obstructive jaundice. Imaging and biopsy confirmed ampullary carcinoma.InterventionFollowing multidisciplinary team (MDT) optimization focusing on glycemic control (target 140–180 mg/dL), preoperative biliary drainage, infection prophylaxis, and immunologic surveillance, a pylorus-preserving PD (PPPD) was performed.OutcomeThe postoperative course was stable with no biochemical leak or clinically relevant postoperative pancreatic fistula (POPF). Histopathology revealed pT2N0 (Stage I) ampullary carcinoma (intestinal-type) with focal lymphovascular invasion (LVI). Interestingly, regional lymph nodes showed CLL infiltration but were negative for metastasis.ConclusionThis case shows that structured MDT optimization and adherence to ERAS protocols enabled safe curative-intent PD in this patient with stable CLL and DM. Introduction Adenocarcinoma of the ampulla of Vater accounts for approximately 0.5% of gastrointestinal malignancies and 20% of periampullary tumors [1]. For localized ampullary adenocarcinoma, complete surgical resection—most commonly pancreaticoduodenectomy—is the only potentially curative treatment, with long‑term survival reported primarily in patients undergoing curative resection [2]. However, PD remains one of the most complex abdominal procedures, historically associated with morbidity rates exceeding 30% and mortality rates of 1–5% even in high-volume centers [3]. These risks are significantly magnified in patients with pre-existing medical comorbidities. Type 2 diabetes mellitus (DM) is a common comorbidity and an established independent and modifiable risk factor for postoperative complications following PD, including surgical site infections (SSI), pancreatic fistula, and sepsis [4]. Concurrently, chronic lymphocytic leukemia (CLL), the most common adult leukemia in the Western world, introduces a state of inherent immune dysregulation and hypogammaglobulinemia, further elevating the risk of infectious complications [5]. The coexistence of CLL, even in a stable, untreated Rai Stage I phase, introduces unique challenges. While major surgery is generally not contraindicated [6], CLL-associated immune dysregulation increases infection risk [5]. Even in early-stage CLL, subtle but clinically relevant immune dysregulation may be present despite the absence of advanced disease or overt cytopenias [7, 8], necessitating a structured multidisciplinary approach to optimize modifiable risks. This patient’s combination of CLL‑related immune dysregulation and diabetes‑associated metabolic risks placed him at higher perioperative risk than a patient without these comorbidities. This report describes the successful surgical management of a patient with DM and indolent CLL who underwent pylorus-preserving PD, focusing on the clinical decision-making and perioperative optimization strategies that led to a complication-free outcome. This case report has been reported in line with the SCARE 2020 criteria [9]. Case presentation Patient information and presentation A 66-year-old man presented with a three-week history of painless obstructive jaundice, progressive icterus, generalized pruritus, and acholic stools. He denied fever, anorexia, and significant weight loss. His medical history was significant for type 2 DM (duration 8 years, HbA1c 7.2%, treated with metformin) and Rai stage I CLL diagnosed five years prior. His CLL remained treatment-naïve under active surveillance with six-monthly hematology follow-up. He also denied any history of cholangitis. He had undergone a right inguinal hernia repair 15 years prior without sequelae. He was a former smoker with a 10-pack-year history. His American Society of Anesthesiologists (ASA) physical status was class III (severe systemic disease). Physical examination demonstrated marked scleral icterus and generalized jaundice. The abdomen was soft and non-tender, without palpable masses or hepatosplenomegaly; a well-healed right inguinal scar was noted. Diagnostic assessment (laboratory evaluation, imaging, endoscopy/biopsy) Laboratory evaluation was consistent with obstructive cholestasis, with a total bilirubin of 8.5 mg/dL (direct 7.0 mg/dL), alkaline phosphatase 320 U/L, and γ-glutamyl transferase 280 U/L; aminotransferases were only mildly elevated. Serum CA 19 − 9 was 85 U/mL (interpreted in the context of biliary obstruction). The complete blood count showed leukocytosis (14,000/µL) with predominant lymphocytosis (80%), consistent with his stable CLL. Preoperative hematologic workup confirmed a normal absolute neutrophil count and an IgG level of 950 mg/dL (normal range: 700–1600 mg/dL), ruling out severe hypogammaglobulinemia. Abdominal ultrasonography, followed by contrast-enhanced computed tomography, demonstrated dilatation of the common bile duct to 15 mm with associated intrahepatic biliary ductal dilatation and a 1.8 cm subtly enhancing soft-tissue lesion at the ampulla of Vater. There was no radiographic evidence of metastatic disease or significant lymphadenopathy. The tumor measured 1.8 cm in greatest dimension on axial imaging and showed no involvement of the superior mesenteric artery, portal vein, or celiac axis. Upper gastrointestinal endoscopy identified a polypoid, ulcerated mass protruding from the ampulla. Endoscopic biopsies revealed fragments of a tubular adenoma with high-grade dysplasia and foci of invasive, moderately differentiated adenocarcinoma. The differential diagnosis included ampullary adenocarcinoma, distal cholangiocarcinoma, and pancreatic head cancer. Based on endoscopic biopsy showing adenocarcinoma of the ampulla, ampullary carcinoma was confirmed and the other diagnoses were excluded. MDT decision and optimization The case was reviewed by a Multidisciplinary Tumor Board involving hepatobiliary surgery, medical oncology, hematology, endocrinology, anesthesiology, and nutrition. Preoperative biliary decompression was achieved via endoscopic retrograde cholangiopancreatography (ERCP) with a 10Fr plastic stent, resulting in a significant decrease in bilirubin levels. From a hematologic standpoint, his CLL remained indolent and treatment-naïve, with no cytopenias, B symptoms, or hypogammaglobulinemia; therefore, cytoreductive or IVIG therapy were not indicated, and surgical resection was supported with heightened attention to infectious risk and appropriate prophylaxis. Endocrinology initiated a basal–bolus insulin protocol preoperatively to optimize perioperative glycemic control, targeting blood glucose levels of 140–180 mg/dL. Nutritional assessment was satisfactory. Specific MDT-driven decisions that deviated from routine care included: 1- Hematology input: Despite the patient’s CLL diagnosis, intravenous immunoglobulin (IVIG) prophylaxis was deemed unnecessary due to a normal IgG level of 950 mg/dL, and standard cefazolin antibiotic prophylaxis was selected over broader coverage based on the absence of neutropenia or active infection.2- Endocrinology input: A basal-bolus insulin protocol was initiated preoperatively, targeting a narrower glycemic range (140–180 mg/dL) than the general inpatient target (< 200 mg/dL), linking tighter control to reduced surgical site infections.3- Scheduling coordination: Surgery was deliberately delayed by four weeks after biliary decompression and performed only after histologic confirmation of ampullary adenocarcinoma from endoscopic biopsy (available within 5 days of presentation)—to allow for glycemic optimization and hematologic stability. This interval balanced the competing risks of disease progression and perioperative complications and was deemed acceptable by the tumor board, as it did not compromise oncologic outcomes. 1- Hematology input: Despite the patient’s CLL diagnosis, intravenous immunoglobulin (IVIG) prophylaxis was deemed unnecessary due to a normal IgG level of 950 mg/dL, and standard cefazolin antibiotic prophylaxis was selected over broader coverage based on the absence of neutropenia or active infection. 1- Hematology input: Despite the patient’s CLL diagnosis, intravenous immunoglobulin (IVIG) prophylaxis was deemed unnecessary due to a normal IgG level of 950 mg/dL, and standard cefazolin antibiotic prophylaxis was selected over broader coverage based on the absence of neutropenia or active infection. 2- Endocrinology input: A basal-bolus insulin protocol was initiated preoperatively, targeting a narrower glycemic range (140–180 mg/dL) than the general inpatient target (< 200 mg/dL), linking tighter control to reduced surgical site infections. 2- Endocrinology input: A basal-bolus insulin protocol was initiated preoperatively, targeting a narrower glycemic range (140–180 mg/dL) than the general inpatient target (< 200 mg/dL), linking tighter control to reduced surgical site infections. 3- Scheduling coordination: Surgery was deliberately delayed by four weeks after biliary decompression and performed only after histologic confirmation of ampullary adenocarcinoma from endoscopic biopsy (available within 5 days of presentation)—to allow for glycemic optimization and hematologic stability. This interval balanced the competing risks of disease progression and perioperative complications and was deemed acceptable by the tumor board, as it did not compromise oncologic outcomes. 3- Scheduling coordination: Surgery was deliberately delayed by four weeks after biliary decompression and performed only after histologic confirmation of ampullary adenocarcinoma from endoscopic biopsy (available within 5 days of presentation)—to allow for glycemic optimization and hematologic stability. This interval balanced the competing risks of disease progression and perioperative complications and was deemed acceptable by the tumor board, as it did not compromise oncologic outcomes. The team proceeded with a curative-intent pylorus-preserving pancreaticoduodenectomy, scheduled approximately four weeks after biliary decompression. Therapeutic intervention The patient underwent an elective pylorus-preserving PD. The procedure was performed via an open midline laparotomy. Intraoperative findings confirmed a 2-cm firm ampullary tumor with no peritoneal or hepatic metastases. A standard resection with regional (D1+) lymphadenectomy was performed. D1 + dissection (removal of peripancreatic lymph node stations 8, 12, 13, and 17) is the standard of care for ampullary carcinoma, balancing adequate nodal sampling for accurate staging with acceptable morbidity [10]. Intraoperatively, enlarged peripancreatic lymph nodes were noted. Frozen section analysis was negative for adenocarcinoma but suggested lymphoid hyperplasia/CLL infiltration. Reconstruction consisted of a duct-to-mucosa pancreaticojejunostomy, hepaticojejunostomy, and gastrojejunostomy. Operative time was 320 min with an estimated blood loss of 550 mL. The pancreatic parenchyma was soft and the main pancreatic duct diameter was approximately 2–3 mm, which corresponds to a moderate (intermediate) fistula risk score [11]. The procedure was performed by a consultant hepatobiliary surgeon (H.E.) with over 10 years of experience in pancreatic surgery, including more than 50 prior pancreaticoduodenectomies. The surgery took place at Ayatollah Taleghani Hospital, a tertiary referral center in Tehran, Iran. The patient was transferred to the surgical intensive care unit postoperatively. Perioperative care followed a formal ERAS protocol: Infection Prophylaxis: Perioperative antibiotic prophylaxis consisted of 2 g intravenous cefazolin administered 60 min prior to incision and continued for no longer than 24 h postoperatively, in accordance with established guidelines [12, 13].Analgesia: Multimodal analgesia (acetaminophen and epidural) was utilized to minimize opioid use.Glycemic Control: Intravenous insulin infusion titrated to maintain 140–180 mg/dL.Drainage Strategy: Two closed‑suction drains were placed near the pancreaticojejunostomy and hepaticojejunostomy for early detection of postoperative pancreatic fistula and bile leak. Infection Prophylaxis: Perioperative antibiotic prophylaxis consisted of 2 g intravenous cefazolin administered 60 min prior to incision and continued for no longer than 24 h postoperatively, in accordance with established guidelines [12, 13]. Infection Prophylaxis: Perioperative antibiotic prophylaxis consisted of 2 g intravenous cefazolin administered 60 min prior to incision and continued for no longer than 24 h postoperatively, in accordance with established guidelines [12, 13]. Analgesia: Multimodal analgesia (acetaminophen and epidural) was utilized to minimize opioid use. Analgesia: Multimodal analgesia (acetaminophen and epidural) was utilized to minimize opioid use. Glycemic Control: Intravenous insulin infusion titrated to maintain 140–180 mg/dL. Glycemic Control: Intravenous insulin infusion titrated to maintain 140–180 mg/dL. Drainage Strategy: Two closed‑suction drains were placed near the pancreaticojejunostomy and hepaticojejunostomy for early detection of postoperative pancreatic fistula and bile leak. Drainage Strategy: Two closed‑suction drains were placed near the pancreaticojejunostomy and hepaticojejunostomy for early detection of postoperative pancreatic fistula and bile leak. Postoperative course He was extubated on postoperative day (POD) 1 and transferred to the surgical ward. Glycemic control was maintained with insulin. He ambulated on POD1 and began a clear liquid diet on POD4, advancing rapidly. Abdominal drains were removed between POD5-7 after confirming low amylase levels (no biochemical leak or clinically relevant postoperative pancreatic fistula (POPF) per Study Group on Pancreatic Surgery 2016 criteria). He developed no evidence of delayed gastric emptying, hemorrhage, or surgical site infection. A clinical timeline is provided in Table 1. Table 1Timeline of clinical eventsDateEventOutcomeWeek 0Symptom onsetPainless jaundice and pruritusWeek 3Initial PresentationDiagnosis of ampullary mass via CT/EndoscopyWeek 4Biliary DecompressionERCP with plastic stent; Bilirubin decreased to 2.1 mg/dLWeek 5–7MDT OptimizationGlycemic control and hematologic clearanceWeek 8Surgical InterventionPylorus-preserving PD; No intraoperative complicationsPOD 1Extubation and mobilizationTransferred to the wardPOD 4Oral diet initiationClear liquid diet toleratedPOD 5–7Drain removalNo POPF or bile leakPOD 12DischargeTolerating a soft diet, stable glycemic control6 monthsFollow-upNo recurrence; DM and CLL are stable Table 1Timeline of clinical eventsDateEventOutcomeWeek 0Symptom onsetPainless jaundice and pruritusWeek 3Initial PresentationDiagnosis of ampullary mass via CT/EndoscopyWeek 4Biliary DecompressionERCP with plastic stent; Bilirubin decreased to 2.1 mg/dLWeek 5–7MDT OptimizationGlycemic control and hematologic clearanceWeek 8Surgical InterventionPylorus-preserving PD; No intraoperative complicationsPOD 1Extubation and mobilizationTransferred to the wardPOD 4Oral diet initiationClear liquid diet toleratedPOD 5–7Drain removalNo POPF or bile leakPOD 12DischargeTolerating a soft diet, stable glycemic control6 monthsFollow-upNo recurrence; DM and CLL are stable Timeline of clinical events Final pathology and adjuvant therapy Final histopathological examination confirmed a 2.1 cm, moderately differentiated intestinal-type adenocarcinoma, invading the duodenal muscularis propria (pT2). All surgical margins (pancreatic neck, bile duct, duodenal, retroperitoneal, and vascular) were negative for carcinoma, corresponding to an R0 resection. All 18 retrieved lymph nodes were negative for malignancy (pN0), though several demonstrated architectural effacement by small lymphocytes consistent with CLL involvement. Focal lymphovascular invasion (LVI) was identified focally, while perineural invasion (PNI) was absent. The final stage was pT2N0M0 (AJCC 8th Ed. Stage I). Adjuvant capecitabine chemotherapy was recommended and initiated eight weeks postoperatively based on the intestinal subtype and the presence of focal LVI. Follow up The patient was discharged home on POD12 in good condition, tolerating a soft diet, and with stable glycemic control on his pre-admission metformin dose. At the six-month follow-up, the patient was asymptomatic and had fully resumed his normal activities. Surveillance CT scan showed no evidence of disease recurrence. His DM remained controlled (HbA1c 6.9%), and his CLL continued on a watchful waiting protocol. Patient perspective “The team worked together to manage my leukemia and diabetes while treating the cancer. I felt safe knowing all my conditions were being watched closely.” Discussion CLL and surgical risks This case illustrates successful major oncologic resection in a patient with stable but clinically relevant comorbidities. While stable Rai Stage I CLL is not a contraindication to surgery, patients with CLL have increased perioperative infection risk due to immune dysfunction [7, 8]. Key mitigations include up‑to‑date vaccinations, IgG level assessment (with IVIG if hypogammaglobulinemic), and appropriate antibiotic prophylaxis [5]. Clinical implications of CLL lymph node involvement A critical lesson is the interpretation of intraoperative lymphadenopathy in CLL patients. This case demonstrated CLL infiltration in all 18 retrieved lymph nodes without metastatic carcinoma. Intraoperative frozen section of enlarged lymph nodes is recommended, as CLL can mimic metastatic disease. Importantly, CLL in regional nodes does not alter oncologic staging (AJCC 8th edition excludes hematologic conditions from nodal staging for solid tumors [14]). Pathologists should distinguish CLL infiltration (monomorphic CD5+, CD23 + small lymphocytes) from low-grade lymphoma [15]. For surgeons, regional lymphadenopathy in a CLL patient should prompt frozen section before extending lymphadenectomy beyond the standard template. MDT optimization and ERAS Endocrinology co‑management achieved glycemic control (140–180 mg/dL), a modifiable risk factor linked to reduced SSI risk and consistent with current guideline recommendations [4, 16]. Adherence to ERAS protocols (early mobilization, goal‑directed fluids, early nutrition) reduces ileus and length of stay [17]. Multimodal analgesia facilitated early recovery; recent evidence supports liposomal bupivacaine as an effective ERAS‑aligned analgesic strategy, though it was not used here [18]. A pylorus‑preserving PD was selected because the tumor was localized to the periampullary region; this approach preserves gastric continuity and offers equivalent oncologic outcomes to the classic Whipple procedure while potentially improving postoperative nutritional recovery [19]. ERAS and older patients ERAS principles are essential for reducing the physiological impact of PD in older patients [17, 20]. Structured perioperative pathways are safe for appropriately selected older patients, with functional status guiding selection beyond chronological age [20, 21]. Oncologic considerations Despite pT2N0 staging, focal lymphovascular invasion (LVI) was considered a high-risk feature, associated with adverse prognosis in ampullary tumors [22]. Current guidelines recommend fluoropyrimidine-based adjuvant chemotherapy (e.g., capecitabine) for high‑risk features [23]. The patient’s stable CLL did not contraindicate standard adjuvant therapy [5]. Lessons to remember Early-stage CLL is not a contraindication to major oncologic surgery; however, careful multidisciplinary evaluation and perioperative infection risk management are advisable.In patients with CLL, intraoperative lymphadenopathy may reflect leukemic infiltration rather than metastatic carcinoma; confirm before extending lymphadenectomy.Multidisciplinary optimization and ERAS adherence can significantly improve outcomes after pancreaticoduodenectomy, even in complex patients. Early-stage CLL is not a contraindication to major oncologic surgery; however, careful multidisciplinary evaluation and perioperative infection risk management are advisable. Early-stage CLL is not a contraindication to major oncologic surgery; however, careful multidisciplinary evaluation and perioperative infection risk management are advisable. In patients with CLL, intraoperative lymphadenopathy may reflect leukemic infiltration rather than metastatic carcinoma; confirm before extending lymphadenectomy. In patients with CLL, intraoperative lymphadenopathy may reflect leukemic infiltration rather than metastatic carcinoma; confirm before extending lymphadenectomy. Multidisciplinary optimization and ERAS adherence can significantly improve outcomes after pancreaticoduodenectomy, even in complex patients. Multidisciplinary optimization and ERAS adherence can significantly improve outcomes after pancreaticoduodenectomy, even in complex patients. Limitations This single case report is not generalizable to all CLL and DM patients undergoing PD. The patient had early-stage CLL (Rai I) without cytopenias or hypogammaglobulinemia, so outcomes may differ for patients with advanced or treated CLL. Additionally, the favorable outcome may reflect selection bias, as the patient was deemed fit for surgery by the MDT. We did not formally calculate a validated fistula risk score; the pancreatic texture and duct diameter were estimated intraoperatively rather than measured precisely, which limits objective interpretation of the absence of postoperative pancreatic fistula. Long-term oncologic follow-up is still ongoing. Conclusion This case demonstrates that curative-intent pancreaticoduodenectomy can be performed safely in select patients with stable untreated CLL and DM when a structured multidisciplinary approach is followed. Practical take-home points include: 1) obtain preoperative hematology consultation to confirm CLL stability; 2) aim for glycemic control of 140–180 mg/dL; 3) use standard antibiotic prophylaxis unless neutropenia is present; 4) interpret intraoperative lymphadenopathy cautiously; and 5) adhere to ERAS protocols.